Pharmacogenetic DNA Bank View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2009-2015

ABSTRACT

Aims of Research Proposal: 1. To build a DNA bank in association with a comprehensive database of treatment outcomes and toxicities of cancer patients. 2. To carry out genotyping of potential candidate genes in relation to specific anti-cancer agents and to correlate genotype with treatment outcomes and toxicities. The investigators hypothesize that genetic variations between different individuals and ethnic groups may account for inter-individual and inter-ethnic differences in treatment response and toxicities to anti-cancer therapy. The understanding of the contribution of these genetic variations may help to individualize therapy to optimize treatment outcomes and reduce toxicities. Patients will be recruited from the National University Hospital Cancer Centre. Any individual aged 18 or above who has been diagnosed with cancer is eligible. 20 ml of blood will be collected from each subject for DNA extraction and pharmacogenetics analysis. At the time of recruitment, demographic characteristics, cancer history, and past and present cancer treatment history of the study subject will be collected. The patients' progress will be followed up periodically (approximately every 6 months) through the medical records, and subsequent cancer treatments, progression of cancer, and survival outcome will be updated. Follow-up will occur until death. Important treatment information that will be collected include the drug regimen, drug doses, intent of treatment, aematologic and non-haematologic toxicities, and hospitalization episodes that may be related to treatment. Known functional single nucleotide polymorphisms (SNPs) of drug metabolizing enzymes, transporters and targets of different anti-cancer agents will be characterized. More comprehensive genotyping will be carried out in 'outliers' who experience exceptional toxicity or biological response to identify novel functional SNPs using high throughput sequencing techniques. Correlation will be made between genotype and treatment-related outcomes (tumor response, progression-free survival) and toxicities. For selected patients, lymphoblastoid transformation will be carried out to maintain an infinite supply of DNA. More... »

URL

https://clinicaltrials.gov/show/NCT00941200

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3142", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Aims of Research Proposal: 1. To build a DNA bank in association with a comprehensive database of treatment outcomes and toxicities of cancer patients. 2. To carry out genotyping of potential candidate genes in relation to specific anti-cancer agents and to correlate genotype with treatment outcomes and toxicities. The investigators hypothesize that genetic variations between different individuals and ethnic groups may account for inter-individual and inter-ethnic differences in treatment response and toxicities to anti-cancer therapy. The understanding of the contribution of these genetic variations may help to individualize therapy to optimize treatment outcomes and reduce toxicities. Patients will be recruited from the National University Hospital Cancer Centre. Any individual aged 18 or above who has been diagnosed with cancer is eligible. 20 ml of blood will be collected from each subject for DNA extraction and pharmacogenetics analysis. At the time of recruitment, demographic characteristics, cancer history, and past and present cancer treatment history of the study subject will be collected. The patients' progress will be followed up periodically (approximately every 6 months) through the medical records, and subsequent cancer treatments, progression of cancer, and survival outcome will be updated. Follow-up will occur until death. Important treatment information that will be collected include the drug regimen, drug doses, intent of treatment, aematologic and non-haematologic toxicities, and hospitalization episodes that may be related to treatment. Known functional single nucleotide polymorphisms (SNPs) of drug metabolizing enzymes, transporters and targets of different anti-cancer agents will be characterized. More comprehensive genotyping will be carried out in 'outliers' who experience exceptional toxicity or biological response to identify novel functional SNPs using high throughput sequencing techniques. Correlation will be made between genotype and treatment-related outcomes (tumor response, progression-free survival) and toxicities. For selected patients, lymphoblastoid transformation will be carried out to maintain an infinite supply of DNA.", 
    "endDate": "2015-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00941200", 
    "keywords": [
      "DNA bank", 
      "Research", 
      "association", 
      "comprehensive database", 
      "treatment outcome", 
      "toxicity", 
      "cancer patient", 
      "genotyping", 
      "potential candidate gene", 
      "relation", 
      "anti-cancer agent", 
      "genotype", 
      "genetic variation", 
      "different individual", 
      "ethnic group", 
      "ethnic difference", 
      "treatment response", 
      "anti-cancer therapy", 
      "contribution", 
      "therapy", 
      "patient", 
      "University Hospital", 
      "Neoplasm", 
      "blood", 
      "DNA extraction", 
      "pharmacogenetics", 
      "recruitment", 
      "demographic characteristic", 
      "cancer history", 
      "treatment history", 
      "patient progress", 
      "medical record", 
      "subsequent cancer", 
      "survival outcome", 
      "follow-up", 
      "death", 
      "treatment information", 
      "drug regimen", 
      "drug dose", 
      "intent", 
      "hospitalization", 
      "single nucleotide polymorphism", 
      "drug metabolizing enzyme", 
      "transporter", 
      "target", 
      "outlier", 
      "biological response", 
      "functional single nucleotide polymorphism", 
      "high-throughput sequencing", 
      "correlation", 
      "related outcome", 
      "tumor response", 
      "Disease-Free Survival", 
      "selected patient", 
      "transformation", 
      "infinite", 
      "DNA"
    ], 
    "name": "Pharmacogenetic DNA Bank", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00941200"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:23", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00007.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.412106.0", 
        "type": "Organization"
      }
    ], 
    "startDate": "2009-04-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1007/s10549-006-9428-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007965097", 
          "https://doi.org/10.1007/s10549-006-9428-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1172/jci118830", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052169575"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00941200"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00941200'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00941200'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00941200'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00941200'


 

This table displays all metadata directly associated to this object as RDF triples.

83 TRIPLES      16 PREDICATES      74 URIs      66 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00941200 schema:about anzsrc-for:3142
2 schema:description Aims of Research Proposal: 1. To build a DNA bank in association with a comprehensive database of treatment outcomes and toxicities of cancer patients. 2. To carry out genotyping of potential candidate genes in relation to specific anti-cancer agents and to correlate genotype with treatment outcomes and toxicities. The investigators hypothesize that genetic variations between different individuals and ethnic groups may account for inter-individual and inter-ethnic differences in treatment response and toxicities to anti-cancer therapy. The understanding of the contribution of these genetic variations may help to individualize therapy to optimize treatment outcomes and reduce toxicities. Patients will be recruited from the National University Hospital Cancer Centre. Any individual aged 18 or above who has been diagnosed with cancer is eligible. 20 ml of blood will be collected from each subject for DNA extraction and pharmacogenetics analysis. At the time of recruitment, demographic characteristics, cancer history, and past and present cancer treatment history of the study subject will be collected. The patients' progress will be followed up periodically (approximately every 6 months) through the medical records, and subsequent cancer treatments, progression of cancer, and survival outcome will be updated. Follow-up will occur until death. Important treatment information that will be collected include the drug regimen, drug doses, intent of treatment, aematologic and non-haematologic toxicities, and hospitalization episodes that may be related to treatment. Known functional single nucleotide polymorphisms (SNPs) of drug metabolizing enzymes, transporters and targets of different anti-cancer agents will be characterized. More comprehensive genotyping will be carried out in 'outliers' who experience exceptional toxicity or biological response to identify novel functional SNPs using high throughput sequencing techniques. Correlation will be made between genotype and treatment-related outcomes (tumor response, progression-free survival) and toxicities. For selected patients, lymphoblastoid transformation will be carried out to maintain an infinite supply of DNA.
3 schema:endDate 2015-12-01T00:00:00Z
4 schema:keywords DNA
5 DNA bank
6 DNA extraction
7 Disease-Free Survival
8 Neoplasm
9 Research
10 University Hospital
11 anti-cancer agent
12 anti-cancer therapy
13 association
14 biological response
15 blood
16 cancer history
17 cancer patient
18 comprehensive database
19 contribution
20 correlation
21 death
22 demographic characteristic
23 different individual
24 drug dose
25 drug metabolizing enzyme
26 drug regimen
27 ethnic difference
28 ethnic group
29 follow-up
30 functional single nucleotide polymorphism
31 genetic variation
32 genotype
33 genotyping
34 high-throughput sequencing
35 hospitalization
36 infinite
37 intent
38 medical record
39 outlier
40 patient
41 patient progress
42 pharmacogenetics
43 potential candidate gene
44 recruitment
45 related outcome
46 relation
47 selected patient
48 single nucleotide polymorphism
49 subsequent cancer
50 survival outcome
51 target
52 therapy
53 toxicity
54 transformation
55 transporter
56 treatment history
57 treatment information
58 treatment outcome
59 treatment response
60 tumor response
61 schema:name Pharmacogenetic DNA Bank
62 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00941200
63 schema:sdDatePublished 2019-03-07T15:23
64 schema:sdLicense https://scigraph.springernature.com/explorer/license/
65 schema:sdPublisher N4e7beafc5f2d4661a03f5f4b2e93cfd9
66 schema:sponsor https://www.grid.ac/institutes/grid.412106.0
67 schema:startDate 2009-04-01T00:00:00Z
68 schema:subjectOf sg:pub.10.1007/s10549-006-9428-0
69 https://doi.org/10.1172/jci118830
70 schema:url https://clinicaltrials.gov/show/NCT00941200
71 sgo:license sg:explorer/license/
72 sgo:sdDataset clinical_trials
73 rdf:type schema:MedicalStudy
74 N4e7beafc5f2d4661a03f5f4b2e93cfd9 schema:name Springer Nature - SN SciGraph project
75 rdf:type schema:Organization
76 anzsrc-for:3142 schema:inDefinedTermSet anzsrc-for:
77 rdf:type schema:DefinedTerm
78 sg:pub.10.1007/s10549-006-9428-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007965097
79 https://doi.org/10.1007/s10549-006-9428-0
80 rdf:type schema:CreativeWork
81 https://doi.org/10.1172/jci118830 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052169575
82 rdf:type schema:CreativeWork
83 https://www.grid.ac/institutes/grid.412106.0 schema:Organization
 




Preview window. Press ESC to close (or click here)


...